ValiRx awarded fifth US patent for VAL401 cancer drug
Clinical stage biotech ValiRx Plc (LON:VAL) has been awarded a fifth patent for its novel cancer treatment drug VAL401. The patent has been awarded by the US Patent Office and covers the use of VAL401 in the treatment of prostate adenocarcinoma – the most …